Farina, Juan M.

Background Immune checkpoint inhibitors (ICI) improve cancer outcomes but are associated with increased atherosclerotic cardiovascular risk. Opportunistic coronary artery calcium (CAC) assessment from routine non-gated computed tomography (CT) using artificial intelligence (AI) may enable rapid cardiovascular risk stratification in this population. We evaluated the association between AI-derived CAC (AI-CAC) scores and 1-year myocardial infarction (MI) and all-cause mortality in patients receiving ICI therapy. Methods We conducted a retrospective multicenter study across three Mayo Clinic sites including patients who underwent chest CT within 3 months prior to ICI initiation between 2011 and 2022. Patients with prior coronary revascularization were excluded. AI-CAC scores derived from non-gated CT scans were categorized as 0, 1–99, 100–399, and ≥400. Cox regression analyses assessed associations with 1-year MI and all-cause mortality. Results Among 1,873 patients (mean age 66 years; 43% women), lung cancer was most common (50.3%), and 91% had at least one cardiovascular risk factor. Higher CAC burden was associated with increased 1-year MI risk (overall p=0.0032). AI-CAC was not associated with all-cause mortality (p=0.79), likely reflecting high cancer-related mortality (50.7% at 1 year). Only 15% of patients were receiving statins despite one-third having CAC >100. Conclusions Opportunistic AI-CAC assessment from routine CT scans provides modest prognostic value for MI risk among patients receiving ICI therapy and may identify opportunities to optimize preventive cardiovascular care. Elevated CAC should prompt risk factor modification rather than influence ICI treatment decisions. Prospective studies are warranted to evaluate clinical implementation and outcomes.

Background. Liver transplant recipients face high risks of cardiometabolic events after transplant, driven by posttransplant weight gain, diabetes, hypertension, as well as immunosuppression-related side effects. Glucagon-like peptide-1 receptor agonists (GLP1RAs) improve metabolic and cardiorenal outcomes in nontransplant populations, but their role in liver transplant recipients remains understudied. Methods. This retrospective cohort study used TriNetX data (January 2010–December 2023) to compare outcomes in liver transplant recipients prescribed GLP1RAs (semaglutide, dulaglutide, liraglutide) within 1-mo posttransplant (n = 546) versus nonusers (n = 37 153). Propensity score matching (1:1) balanced demographics, comorbidities, and medications (n = 541 per group). Outcomes included mortality, hospitalizations, cardiovascular/renal/respiratory events, and graft outcomes. Results. Over a mean follow-up 838.5 d (SD 291.9) in the GLP1RA cohort and 884.3 d (SD 313.7) in the non-GLP1RA group, GLP1RA use was associated with a 43% lower all-cause mortality (7.0% versus 12.9%; hazard ratio [HR], 0.566; 95% confidence interval [CI], 0.381-0.841) and 39% fewer hospitalizations (60.4% versus 74.5%; HR, 0.613; 95% CI, 0.530-0.710). Acute heart failure (HR, 0.386; 95% CI, 0.285-0.524), renal failure/dialysis (HR, 0.489; 95% CI, 0.413-0.579), and respiratory failure (HR, 0.484; 95% CI, 354-0.662) risks were significantly reduced. No differences were observed in graft failure/rejection, myocardial infarction, stroke, atrial fibrillation/flutter, ventricular tachycardia, or ischemic optic neuropathy. Conclusions. Early GLP1RA initiation in liver transplant recipients was associated with reduced mortality, hospitalizations, respiratory, and cardiorenal complications without compromising graft safety. These findings support GLP1RAs as a promising adjunct therapy, warranting prospective trials to confirm benefits in this high-risk population.

This cohort study examines the association of bruton tyrosine kinase inhibitor therapy in B-cell malignant disease with increased risk of pericardial effusion and cardiovascular outcomes.